ALKEM LABORATORIES SHARE PRICE

Alkem Laboratories Ltd. is a multinational pharmaceutical company based in India. It manufactures and markets pharmaceutical formulations, generics, and nutraceuticals. It was incorporated in 1973, with its headquarters in Mumbai. In the June 2022 quarter, Alkem Laboratories Ltd. recorded a total income of Rs 2,627.79 crore, up 4.93% against Rs 2,504.38 crore in the March 2022 quarter. The company’s market capitalisation on 10 October 2022 stood at Rs 37,957 crore.

The company is listed on the Bombay Stock Exchange with the code 539523, and on the National Stock Exchange with the code ALKEM.

Alkem Laboratories Ltd. is a leading player in the branded and generic drugs space. It has a significant brand share in the cardiovascular, anti-diabetic, central nervous system, anti-osteoporosis, immunosuppressants, anti-malarial, and nutraceutical segments. The company leads the Indian market in the pain management and anti-infective segments. Alkem was awarded the 31st rank in India’s Best Companies to Work for in 2022 by the Great Place to Work Institute.

The company’s shareholding pattern as of 30 June 2022 represented a 57.14% promoter stake, 5.67% foreign institutional investor stake, 14.1% domestic institutional investor stake, and 23.09% public stake. During the June 2022 quarter, promoter holdings increased from 57.13% to 57.14%, mutual fund holdings increased from 7.52% to 7.85%, and FII holdings also increased from 5.41% to 5.67%.

The company’s board of directors comprise Mr Basudeo N Singh, Mr Sandeep Singh, Mr Mritunjay Singh, Mr Sarvesh Singh, Mr Srinivas Singh, Mr Arun Purwar, Mr Narendra K Aneja, Dr Dheeraj Sharma, Ms Sangeeta K Singh, and Ms Sudha Ravi. The auditors are BSR & Co. LLP. On 30 June 2022, the company recorded a total of 11.96 crore shares outstanding.

On 10 October 2022, the company’s BSE share price closed at Rs 3,172.80. Alkem Laboratories Ltd.’s NSE share price closed at Rs 3,174.65. The company’s 52-week high share price was Rs 3,990, while the 52-week low for the company’s share price was Rs 2,828. Alkem Laboratories Ltd.’s share gave investors a one-year return of -18.79%.

The company’s peers in the pharmaceutical sector include Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Divis Laboratories Ltd., and Cipla Ltd.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Alkem Laboratories share price as on 20 Jun 2025 is Rs. 4782. Over the past 6 months, the Alkem Laboratories share price has decreased by 12.95% and in the last one year, it has decreased by 8.36%. The 52-week low for Alkem Laboratories share price was Rs. 4491.65 and 52-week high was Rs. 6439.9.

Alkem Laboratories Ltd. is a multinational pharmaceutical company based in India. It manufactures and markets pharmaceutical formulations, generics, and nutraceuticals. It was incorporated in 1973, with its headquarters in Mumbai. In the June 2022 quarter, Alkem Laboratories Ltd. recorded a total income of Rs 2,627.79 crore, up 4.93% against Rs 2,504.38 crore in the March 2022 quarter. The company’s market capitalisation on 10 October 2022 stood at Rs 37,957 crore.

The company is listed on the Bombay Stock Exchange with the code 539523, and on the National Stock Exchange with the code ALKEM.

Alkem Laboratories Ltd. is a leading player in the branded and generic drugs space. It has a significant brand share in the cardiovascular, anti-diabetic, central nervous system, anti-osteoporosis, immunosuppressants, anti-malarial, and nutraceutical segments. The company leads the Indian market in the pain management and anti-infective segments. Alkem was awarded the 31st rank in India’s Best Companies to Work for in 2022 by the Great Place to Work Institute.

The company’s shareholding pattern as of 30 June 2022 represented a 57.14% promoter stake, 5.67% foreign institutional investor stake, 14.1% domestic institutional investor stake, and 23.09% public stake. During the June 2022 quarter, promoter holdings increased from 57.13% to 57.14%, mutual fund holdings increased from 7.52% to 7.85%, and FII holdings also increased from 5.41% to 5.67%.

The company’s board of directors comprise Mr Basudeo N Singh, Mr Sandeep Singh, Mr Mritunjay Singh, Mr Sarvesh Singh, Mr Srinivas Singh, Mr Arun Purwar, Mr Narendra K Aneja, Dr Dheeraj Sharma, Ms Sangeeta K Singh, and Ms Sudha Ravi. The auditors are BSR & Co. LLP. On 30 June 2022, the company recorded a total of 11.96 crore shares outstanding.

On 10 October 2022, the company’s BSE share price closed at Rs 3,172.80. Alkem Laboratories Ltd.’s NSE share price closed at Rs 3,174.65. The company’s 52-week high share price was Rs 3,990, while the 52-week low for the company’s share price was Rs 2,828. Alkem Laboratories Ltd.’s share gave investors a one-year return of -18.79%.

The company’s peers in the pharmaceutical sector include Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Divis Laboratories Ltd., and Cipla Ltd.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose

Alkem Laboratories share price as on 20 Jun 2025 is Rs. 4782. Over the past 6 months, the Alkem Laboratories share price has decreased by 12.95% and in the last one year, it has decreased by 8.36%. The 52-week low for Alkem Laboratories share price was Rs. 4491.65 and 52-week high was Rs. 6439.9.